Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.600
+0.220 (15.94%)
At close: Oct 22, 2026, 4:00 PM EDT
1.519
-0.081 (-5.06%)
Pre-market: Oct 23, 2026, 4:00 AM EDT
Actinium Pharmaceuticals Revenue
Actinium Pharmaceuticals had revenue of $35.00M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $35.09M. In the year 2025, Actinium Pharmaceuticals had annual revenue of $90.00K. That makes Actinium Pharmaceuticals the 30,360th largest company in the world by revenue and 4,023rd in the United States.
Revenue (ttm)
$35.09M
Revenue Growth
n/a
P/S Ratio
1.43
Revenue / Employee
$1,299,630
Employees
27
Market Cap
50.31M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 90.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 81.00K | -949.00K | -92.14% |
| Dec 31, 2022 | 1.03M | -114.00K | -9.97% |
| Dec 31, 2021 | 1.14M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Alterity Therapeutics | 2.50M |
| Hyperion DeFi | 1.40M |
| ImageneBio | 800.00K |
| Mereo BioPharma Group | 500.00K |
| Serina Therapeutics | 130.00K |
| INmune Bio | 50.00K |
ATNM News
- 2 days ago - Actinium Pharmaceuticals’ ATNM-400 shows anti-tumor activity in prostate cancer - TheFly
- 2 days ago - Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer - PRNewsWire
- 2 days ago - Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models - PRNewsWire
- 3 days ago - Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 - PRNewsWire
- 6 days ago - Actinium Pharmaceuticals Announces Inducement Grants to New Employees - PRNewsWire
- 6 days ago - Actinium Pharmaceuticals to present ATNM-400 data at EANM - TheFly
- 6 days ago - Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models - PRNewsWire
- 6 days ago - Actinium Pharmaceuticals Proxy statement: Proxy filing - Filings